Abstract
We have shown previously that the function of Ycf1p, yeast ortholog of multidrug resistance-associated protein 1 (MRP1), is regulated by yeast casein kinase 2α (Cka1p) via phosphorylation at Ser251. In this study, we explored whether casein kinase 2α (CK2α), the human homolog of Cka1p, regulates MRP1 by phosphorylation at the semiconserved site Thr249. Knockdown of CK2α in MCF7-derived cells expressing MRP1 [MRP1 CK2α(−)] resulted in increased doxorubicin sensitivity. MRP1-dependent transport of leukotriene C4 and estradiol-17β-d-glucuronide into vesicles derived from MRP1 CK2α(−) cells was decreased compared with MRP1 vesicles. Moreover, mutation of Thr249 to alanine (MRP1-T249A) also resulted in decreased MRP1-dependent transport, whereas a phosphomimicking mutation (MRP1-T249E) led to dramatic increase in MRP1-dependent transport. Studies in tissue culture confirmed these findings, showing increased intracellular doxorubicin accumulation in MRP1 CK2α(−) and MRP1-T249A cells compared with MRP1 cells. Inhibition of CK2 kinase by 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole resulted in increased doxorubicin accumulation in MRP1 cells, but not in MRP1 CK2α(−), MRP1-T249A, or MRP1-T249E cells, suggesting that CK2α regulates MRP1 function via phosphorylation of Thr249. Indeed, CK2α and MRP1 interact physically, and recombinant CK2 phosphorylates MRP1-derived peptide in vitro in a Thr249-dependent manner, whereas knockdown of CK2α results in decreased phosphorylation at MRP1-Thr249. The role of CK2 in regulating MRP1 was confirmed in other cancer cell lines where CK2 inhibition decreased MRP1-mediated efflux of doxorubicin and increased doxorubicin cytotoxicity. This study supports a model in which CK2α potentiates MRP1 function via direct phosphorylation of Thr249.
Footnotes
↵
The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
This project was supported in part by the National Institutes of Health National Center for Research Resources [Grant 5P20-RR020171-09]; and the National Institutes of Health National Institute of General Medical Sciences [Grant 8P20-GM103486-09].
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
ABBREVIATIONS:
- ABC
- ATP-binding cassette
- MRP
- multidrug resistance-associated protein
- NTE
- N-terminal extension
- LTC4
- leukotriene C4
- E217βG
- estradiol-17β-d-glucuronide
- CK2
- casein kinase 2
- Ycf1p
- yeast cadmium factor 1
- Cka1p
- yeast casein kinase CK2α
- CHX
- cycloheximide
- DMAT
- 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole
- TBBz
- 4,5,6,7-tetrabromo-benzimidazole
- MK571
- (E)-3-[[[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-[[3-dimethylamino)-3-oxopropyl]thio]methyl]thio]-propanoic acid
- PSC883
- valspodar
- DMEM
- Dulbecco's modified Eagle's medium
- FBS
- fetal bovine serum
- G418
- Geneticin
- MTT
- 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
- PBS
- phosphate-buffered saline
- BSA
- bovine serum albumin
- RIPA
- radioimmunoprecipitation assay
- PAGE
- polyacrylamide gel electrophoresis
- AUC
- area under the curve
- TS
- Tris-sucrose
- shRNA
- short hairpin RNA
- FTC
- fumitremorgin C
- coIP
- coimmunoprecipitation
- ANOVA
- analysis of variance.
- Received February 13, 2012.
- Accepted June 13, 2012.
- Copyright © 2012 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|